Glucagon-like Peptide-1 (GLP-1) is an important incretin hormone which acts as a powerful insulin secretagogue. Defects in GLP-1 synthesis and secretion are thought to be part of the pathogenesis of type 2 diabetes. Furthermore GLP-1 based therapy is an important part of the therapeutic armamentarium for the treatment of type 2 diabetes. The GLP-1 receptor (GLP1R) is the principal site of action of GLP-1 and GLP-1 receptor agonists like exenatide and liraglutide. The gene coding for this receptor, GLP1R, is highly polymorphic and contains numerous non-synonymous Single Nucleotide Polymorphisms (nsSNPs) which could potentially alter response to endogenous or exogenous GLP-1 or GLP-1R agonists. Indeed there is some in vitro data to support this concept. We propose to utilize a hyperglycemic clamp to test the insulin secretory response to infused GLP-1 in healthy volunteers to determine the effect of genetic variation in GLP1R on response to GLP-1.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
88
GLP-1 infused at 0.75 pmol/kg/min from 121-180 minutes, GLP-1 infused at 1.55 pmol/kg/min from 181-240 minutes,
Mayo Clinic
Rochester, Minnesota, United States
Insulin Secretion at 150-180 Minutes.
The 180 minute value represents the mean of the values obtained at 150, 160, 170, and 180 minutes.
Time frame: 150 - 180 minutes after GLP-1 infusion
Insulin Secretion at 210-240 Minutes
The 240 minute value represents the mean of values obtained at 210, 220, 230, and 240 minutes.
Time frame: 210 - 240 minutes after GLP-1 infusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.